Actinium Pharmaceuticals, Inc. (NYSE: ATNM) had its "overweight" rating re-affirmed by analysts at Stephens. They now have a $5.00 price target on the stock.
Actinium Pharmaceuticals Highlights Antibody Radiation Conjugate Program Developments and Reports Financial Results for the Third Quarter 2024 [Yahoo! Finance]
Actinium Pharmaceuticals Highlights Antibody Radiation Conjugate Program Developments and Reports Financial Results for the Third Quarter 2024
Actinium Pharmaceuticals, Inc. (NYSE: ATNM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock.
Actinium Pharmaceuticals, Inc. (NYSE: ATNM) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.